Selected research
Industry Research
Antisense and RNAi Therapeutics Industry Research Report 2026
Market perspective
The global Antisense and RNAi Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antisense and RNAi Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antisense and RNAi Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antisense and RNAi Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antisense and RNAi Therapeutics include Roche, Tekmira Pharmaceuticals, Sirnaomics, Silence Therapeutics, Santaris, Isis Pharmaceuticals, Arbutus Biopharma, Antisense Therapeutics and Alnylam Pharmaceuticals. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antisense and RNAi Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antisense and RNAi Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antisense and RNAi Therapeutics Market by Company
Roche
Tekmira Pharmaceuticals
Sirnaomics
Silence Therapeutics
Santaris
Isis Pharmaceuticals
Arbutus Biopharma
Antisense Therapeutics
Alnylam Pharmaceuticals
Antisense and RNAi Therapeutics Segment by Type
RNA Interference
Antisense RNA
Antisense and RNAi Therapeutics Segment by Application
Hospital
Clinic
Antisense and RNAi Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antisense and RNAi Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- RNA Interference
- Antisense RNA
Applications
- Hospital
- Clinic
Companies covered
- Roche
- Tekmira Pharmaceuticals
- Sirnaomics
- Silence Therapeutics
- Santaris
- Isis Pharmaceuticals
- Arbutus Biopharma
- Antisense Therapeutics
- Alnylam Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antisense and RNAi Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 RNA Interference
- 2.2.3 Antisense RNA
- 2.3 Antisense and RNAi Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.4 Assumptions and Limitations
3 Antisense and RNAi Therapeutics Breakdown Data by Type
- 3.1 Global Antisense and RNAi Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Type (2027-2032)
4 Antisense and RNAi Therapeutics Breakdown Data by Application
- 4.1 Global Antisense and RNAi Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antisense and RNAi Therapeutics Market Perspective (2021-2032)
- 5.2 Global Antisense and RNAi Therapeutics Growth Trends by Region
- 5.2.1 Global Antisense and RNAi Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antisense and RNAi Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Antisense and RNAi Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Antisense and RNAi Therapeutics Market Dynamics
- 5.3.1 Antisense and RNAi Therapeutics Industry Trends
- 5.3.2 Antisense and RNAi Therapeutics Market Drivers
- 5.3.3 Antisense and RNAi Therapeutics Market Challenges
- 5.3.4 Antisense and RNAi Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antisense and RNAi Therapeutics Players by Revenue
- 6.1.1 Global Top Antisense and RNAi Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Antisense and RNAi Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antisense and RNAi Therapeutics Head Office and Area Served
- 6.4 Global Antisense and RNAi Therapeutics Players, Product Type & Application
- 6.5 Global Antisense and RNAi Therapeutics Manufacturers Established Date
- 6.6 Global Antisense and RNAi Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antisense and RNAi Therapeutics Market Size (2021-2032)
- 7.2 North America Antisense and RNAi Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antisense and RNAi Therapeutics Market Size (2021-2032)
- 8.2 Europe Antisense and RNAi Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antisense and RNAi Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Antisense and RNAi Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antisense and RNAi Therapeutics Market Size (2021-2032)
- 10.2 South America Antisense and RNAi Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antisense and RNAi Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Antisense and RNAi Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.1.4 Roche Antisense and RNAi Therapeutics Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Tekmira Pharmaceuticals
- 12.2.1 Tekmira Pharmaceuticals Company Information
- 12.2.2 Tekmira Pharmaceuticals Business Overview
- 12.2.3 Tekmira Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.2.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
- 12.2.5 Tekmira Pharmaceuticals Recent Developments
- 12.3 Sirnaomics
- 12.3.1 Sirnaomics Company Information
- 12.3.2 Sirnaomics Business Overview
- 12.3.3 Sirnaomics Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.3.4 Sirnaomics Antisense and RNAi Therapeutics Product Portfolio
- 12.3.5 Sirnaomics Recent Developments
- 12.4 Silence Therapeutics
- 12.4.1 Silence Therapeutics Company Information
- 12.4.2 Silence Therapeutics Business Overview
- 12.4.3 Silence Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.4.4 Silence Therapeutics Antisense and RNAi Therapeutics Product Portfolio
- 12.4.5 Silence Therapeutics Recent Developments
- 12.5 Santaris
- 12.5.1 Santaris Company Information
- 12.5.2 Santaris Business Overview
- 12.5.3 Santaris Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.5.4 Santaris Antisense and RNAi Therapeutics Product Portfolio
- 12.5.5 Santaris Recent Developments
- 12.6 Isis Pharmaceuticals
- 12.6.1 Isis Pharmaceuticals Company Information
- 12.6.2 Isis Pharmaceuticals Business Overview
- 12.6.3 Isis Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
- 12.6.5 Isis Pharmaceuticals Recent Developments
- 12.7 Arbutus Biopharma
- 12.7.1 Arbutus Biopharma Company Information
- 12.7.2 Arbutus Biopharma Business Overview
- 12.7.3 Arbutus Biopharma Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.7.4 Arbutus Biopharma Antisense and RNAi Therapeutics Product Portfolio
- 12.7.5 Arbutus Biopharma Recent Developments
- 12.8 Antisense Therapeutics
- 12.8.1 Antisense Therapeutics Company Information
- 12.8.2 Antisense Therapeutics Business Overview
- 12.8.3 Antisense Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.8.4 Antisense Therapeutics Antisense and RNAi Therapeutics Product Portfolio
- 12.8.5 Antisense Therapeutics Recent Developments
- 12.9 Alnylam Pharmaceuticals
- 12.9.1 Alnylam Pharmaceuticals Company Information
- 12.9.2 Alnylam Pharmaceuticals Business Overview
- 12.9.3 Alnylam Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2021-2026)
- 12.9.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
- 12.9.5 Alnylam Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst